Latest news with #weightlossdrugs
CNN
7 hours ago
- Health
- CNN
Challenging time for NFL, how to elude mosquitoes, ‘Ozempic face': Catch up on the day's stories
5 Things Football Prescription drugs Animal storiesFacebookTweetLink Follow 👋 Welcome to 5 Things PM! For summertime beachgoers, the threat of sharks may loom large, but nature's deadliest predator is actually much smaller. Experts offer tips to make yourself less attractive to mosquitoes. Here's what else you might have missed during your busy day. Late July is usually filled with optimism and excitement for the NFL, but the league is reeling after a gunman targeted its offices in New York City. The shooting thrust a sensitive topic — chronic traumatic encephalopathy, or CTE — into the spotlight just days before preseason games begin, along with a uniquely American problem. Thousands of microplastics so small they can penetrate deep into the lungs are in the air you breathe in your home and car. A new study found that they probably come from the degradation of plastic-filled objects such as carpet, curtains, furniture and textiles. Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after they shed pounds with the help of weight-loss drugs. Thanks to them, the plastic surgery business is booming. With her short hair and unshowy clothing, Fan Chunli looks every bit the middle-aged woman from rural China. Joking about her abusive ex-husband launched the unassuming comedian to stardom, but the authorities aren't laughing. Order a cold drink in Europe and you could be in for an unpleasant surprise. The beverage will probably arrive lukewarm. CNN's travel team explores why Americans' obsession with ice doesn't translate across the pond. GET '5 THINGS' IN YOUR INBOX If your day doesn't start until you're up to speed on the latest headlines, then let us introduce you to your new favorite morning fix. Sign up here for the '5 Things' newsletter. 🧑✈️ 'This is a hoot!' This year marks the 100th anniversary of the iconic Goodyear Blimp. CNN correspondent and flight instructor Pete Muntean took one out for a spin and tried a few maneuvers at a Wisconsin airshow. See how he did. Federal Reserve holds interest rates steady despite pressure from Trump Senate Democrats try to force release of Epstein files using arcane law Jury finds Colorado dentist guilty of murdering his wife 😢 A final goodbye: Thousands of fans paid their respects to Ozzy Osbourne as his hearse made its way through the streets of Birmingham, the English city where he grew up and where his band Black Sabbath formed in 1968. 🌊 How strong was the earthquake off Russia's far eastern coast that prompted tsunami warnings in the US?A. 5.5B. 6.4C. 7.2D. 8.8⬇️ Scroll down for the answer. 👋 We'll see you tomorrow.🧠 Quiz answer: D. The massive 8.8 magnitude quake is tied for the sixth strongest ever recorded.📧 Check out all of CNN's newsletters. Today's edition of 5 Things PM was edited and produced by CNN's Kimberly Richardson and Chris Good.
CNN
8 hours ago
- Health
- CNN
Challenging time for NFL, how to elude mosquitoes, ‘Ozempic face': Catch up on the day's stories
5 Things Football Prescription drugs Animal storiesFacebookTweetLink Follow 👋 Welcome to 5 Things PM! For summertime beachgoers, the threat of sharks may loom large, but nature's deadliest predator is actually much smaller. Experts offer tips to make yourself less attractive to mosquitoes. Here's what else you might have missed during your busy day. Late July is usually filled with optimism and excitement for the NFL, but the league is reeling after a gunman targeted its offices in New York City. The shooting thrust a sensitive topic — chronic traumatic encephalopathy, or CTE — into the spotlight just days before preseason games begin, along with a uniquely American problem. Thousands of microplastics so small they can penetrate deep into the lungs are in the air you breathe in your home and car. A new study found that they probably come from the degradation of plastic-filled objects such as carpet, curtains, furniture and textiles. Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after they shed pounds with the help of weight-loss drugs. Thanks to them, the plastic surgery business is booming. With her short hair and unshowy clothing, Fan Chunli looks every bit the middle-aged woman from rural China. Joking about her abusive ex-husband launched the unassuming comedian to stardom, but the authorities aren't laughing. Order a cold drink in Europe and you could be in for an unpleasant surprise. The beverage will probably arrive lukewarm. CNN's travel team explores why Americans' obsession with ice doesn't translate across the pond. GET '5 THINGS' IN YOUR INBOX If your day doesn't start until you're up to speed on the latest headlines, then let us introduce you to your new favorite morning fix. Sign up here for the '5 Things' newsletter. 🧑✈️ 'This is a hoot!' This year marks the 100th anniversary of the iconic Goodyear Blimp. CNN correspondent and flight instructor Pete Muntean took one out for a spin and tried a few maneuvers at a Wisconsin airshow. See how he did. Federal Reserve holds interest rates steady despite pressure from Trump Senate Democrats try to force release of Epstein files using arcane law Jury finds Colorado dentist guilty of murdering his wife 😢 A final goodbye: Thousands of fans paid their respects to Ozzy Osbourne as his hearse made its way through the streets of Birmingham, the English city where he grew up and where his band Black Sabbath formed in 1968. 🌊 How strong was the earthquake off Russia's far eastern coast that prompted tsunami warnings in the US?A. 5.5B. 6.4C. 7.2D. 8.8⬇️ Scroll down for the answer. 👋 We'll see you tomorrow.🧠 Quiz answer: D. The massive 8.8 magnitude quake is tied for the sixth strongest ever recorded.📧 Check out all of CNN's newsletters. Today's edition of 5 Things PM was edited and produced by CNN's Kimberly Richardson and Chris Good.
Reuters
15 hours ago
- Business
- Reuters
Novo Nordisk slides further on US competition, new CEO concerns
COPENHAGEN, July 30 (Reuters) - Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs in the United States, a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker's value. Novo Nordisk slashed its outlook for 2025 sales growth on Tuesday and said it had appointed veteran insider Maziar Mike Doustdar as its new CEO, tasked with reviving its performance in the United States, the largest market for weight-loss drugs. Novo said the lower sales outlook reflected competition from "compounded" copycats to Wegovy, custom-made medicines that are based on the same ingredients as branded drugs, which took investors by surprise. While Novo said it was intensifying its efforts to regain patients taking copycat drugs and limit unlawful compounding, analysts at Guggenheim said Novo's new 2025 guidance did not assume compounding volumes coming down. Its shares closed down 23% on Tuesday after tumbling as much as 30%. On Wednesday, they had fallen a further 4.1% by 1257 GMT. Novo became Europe's most valuable listed company following the launch of Wegovy in 2021 but its shares have fallen by two-thirds since peaking in June last year on concerns the drugmaker is losing ground in the obesity drug race. Despite the problems, incoming CEO Doustdar said on an investor call on Tuesday that "we are having a fantastic growth right now with Wegovy". "This has really become a severe credibility issue," said Barclays analyst Emily Field. "They don't view the issues that they have as severely as the market does, and that's creating a big problem." Doustdar told investors a priority will be to move faster and improve "commercial execution" but did not reveal any new strategic direction. He currently heads all commercial units globally, minus the United States, which according to analysts at TD Cowen had been "a brighter spot in Novo's commercial efforts, which could help to buoy the current platform as the pipeline advances". Barclays downgraded the stock to "equal-weight" from "overweight". Bank of America also downgraded the stock to "neutral" from "buy".
Yahoo
15-07-2025
- Health
- Yahoo
Connecticut wants to make generic GLP-1s. Will RFK Jr. lend a hand?
Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance program — HUSKY Health, which includes Medicaid and CHIP enrollees — and it could help other states do the same if it succeeds. The bill, signed by Gov. Ned Lamont on July 8, focuses on efforts to control drug prices but has a section dedicated to generic GLP-1 drugs, similar to Novo Nordisk's (NVO) Ozempic and Wegovy and Eli Lilly's (LLY) Mounjaro and Zepbound. Combined, the four drugs have been ballooning the state's spending — contributing costs of $140 million in fiscal year 2024 — a problem plaguing many states. Some states have chosen to restrict or limit who can be prescribed the drugs, while others have stopped covering them altogether. Connecticut expanded coverage in 2023. The new law calls for the Commissioner of Social Services to petition the US Health and Human Services Department (HHS) Secretary Robert F. Kennedy Jr. to exercise the federal government's right to own the patents of GLP-1s and contract with generic manufacturers to produce a version of the drugs in exchange for royalties that Connecticut says it will pay. "The commissioner may enter into a consortium with officials in other states in contracting with such manufacturer for such drugs," according to the state's new law. State Sen. Matt Lesser, who introduced the bill, told Yahoo Finance that other states, both red and blue, have already expressed interest. He said the state has 30 days to submit the petition. "The governor and Sec. Kennedy have known each other for a very long time. So I don't know what conversations they may or may not have had. But, I think we're also having some early conversations," Lesser said of the state's social services commission. HHS did not reply to a request for comment from Yahoo Finance. The power to claim ownership of the patent comes from a section in the US Patent Code, 28 US 1498, which is described by experts as similar to eminent domain. If RFK Jr. accepts Connecticut's request, the drugmakers would be compensated based on a benchmark closer to production costs, not to market rates, according to Robin Feldman, a professor of law and director of the Center for Innovation at the University of California, San Francisco. "So recent cases are royalties of 10% or 7.5%," Feldman told Yahoo Finance. Lamont, meanwhile, signaled caution when signing the bill last week. "While well-intentioned, this provision may present an overreach of Section 1498, which was intended to provide a remedy for patent holders for when the federal government uses patented inventions for its own purposes," he said. "The administration will work collaboratively with the industry, healthcare professionals, and advocates to ensure that provision is implemented as appropriate under federal law." The strategy faces some uncertainty, but it could be coming at just the right time, according to some experts. Connecticut's effort comes as prices have begun to ease in the wake of increased supply from drugmakers Novo Nordisk and Eli Lilly. Both are offering vials at cheaper prices than injectables in direct-to-consumer avenues to counter the massive compounding market. Former Novo Nordisk CEO Lars Jørgensen previously told Yahoo Finance that the compounding market is "approximately as big as our own business." Compounders were initially allowed to provide the copycats without FDA approval when the drugs were in short supply. The FDA has since ended the shortages, but some compounders continue to produce the cheaper copycats, claiming they have protections for "personalized medicine." That debate is making its way through the court system and is currently in the Fifth Circuit Court of Appeals. Lesser said Connecticut considered compounding but wasn't comfortable with the lack of FDA approval for the products. In addition to lower prices, Novo Nordisk's drugs are facing the end of their exclusivity period, which is regulated by the FDA. This is separate from the patents protected by the US Patent Office. While the patents expire in 2031, the FDA exclusivity has already partially expired for semaglutide in recent years On top of all that, generic competition is already on the horizon in Canada, which means a manufacturer is currently setting up production and getting approval from a comparable regulatory body to the FDA, according to Rachel Sachs, a professor of innovation policy and patent law at Washington University in St. Louis. That could also be useful if states decide to import from Canada — and would be quicker than the FDA process to contract with a US-based facility. "So this is a sort of sweet spot for those products, where it would be a particularly impactful time for the (patent) law to be used," Sachs said. The law Connecticut wants HHS to invoke has been used in the past. In 2017, Louisiana invoked the same law to try to get Hepatitis C drugs at a lower cost. At the time, more than 35,000 Medicaid enrollees using the drugs were costing the state $764 million. The drugmaker, Gilead Sciences (GILD), ultimately struck a deal with Louisiana to implement an "innovative payment model," which capped the state's costs. And post-9/11, when there was an anthrax scare, the US government invoked the law to stockpile Bayer's (BAYRY) drug Cipro. Bayer ultimately agreed to lower its price. Recently, North Carolina tried a different strategy by leveraging its relationships with Novo Nordisk and Eli Lilly, which had manufacturing operations in the state last year. It was unsuccessful and had to cut coverage for state employees while keeping coverage for Medicaid beneficiaries. The state petitioned HHS and then-Secretary Xavier Becerra to negotiate lower prices on its behalf but stopped short of invoking the patent law, though some advocacy groups suggested it at the time. It's why experts and advocates are closely watching how RFK Jr. responds to this petition. But so far, the Trump administration has made no progress in its efforts to curb costs, according to Amy Kapczynski, a professor at Yale Law School and expert on intellectual property rights. "The Trump Administration has been weak in addressing drug pricing as a problem, undermining some of the gains of the recent Biden bill to lower drug prices for Medicare," she told Yahoo Finance. "They may not want to do this, and argue that they can't — but really, I see it as a question of political will." UCSF's Feldman echoed a similar sentiment, adding that the situation could end well for the drugmakers too. "There should be a deal to be made that provides very handsome returns for the companies who have brought (these drugs) to society, but in a way that's sustainable and doesn't break the bank," she said. — Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Sign in to access your portfolio
Yahoo
12-07-2025
- Business
- Yahoo
Hims & Hers Health, Inc. (HIMS) Isn't Regarded As A Great Actor By Doctors, Says Jim Cramer
We recently published . Hims & Hers Health, Inc. (NYSE:HIMS) is one of the stocks Jim Cramer recently discussed. Hims & Hers Health, Inc. (NYSE:HIMS) is a well-known digital health platform that allows users to order medicines after securing prescriptions. Despite multiple headwinds in 2025, the shares are still up by 93% year-to-date. Hims & Hers Health, Inc. (NYSE:HIMS)'s shares fell by 42% in February after the firm warned that it might be unable to maintain the availability of crucial weight loss drugs on its platform. Then, after the stock gained 61% by late June, it again crashed and lost 35%. This time around, Hims & Hers Health, Inc. (NYSE:HIMS) suffered as weight loss drug maker Novo Nordisk ended its partnership with the firm. As for Cramer, he commented on the firm's business: Hims & Hers by the way when you talk to doctors, you talk to people in the business, Hims & Hers is regarded as being a not great actor. I think they're a good actor for the people.' Earlier, the CNBC host had discussed short seller sentiment for Hims & Hers Health, Inc. (NYSE:HIMS): 'No matter how much you love these speculative winners, you don't have a gain until you actually ring the register. At the end of last week, for example, Hims & Hers Health, the online healthcare company, was trading at $64. But then yesterday, the stock fell 22 bucks for an almost 35% decline… What I care about is that this stock… [has] almost tripled in two months. If you owned Hims & Hers up almost 200% and you hadn't sold any at that point, you were being a knucklehead. A nurse in a telehealth platform talking with a patient on video call for consultation. Why? Because this is one of the most heavily shorted stocks in the market. 35% of the shares sold short. A lot of people have been betting against it. The haters are plentiful. In that situation, the stock can erupt on any good news. And there was a lot of good news when HIMS was making money with the Wegovy deal. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
